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DEBATE
Con: are we ready to translate Alzheimer’s
disease-modifying therapies to people with down
syndrome?
Elizabeth Head1* and Frederick A Schmitt2
See related debate by Rafii, http://alzres.com/content/6/8/60
Abstract
Background: Adults with Down syndrome develop Alzheimer’s disease neuropathology in an age-dependent
manner. This unique feature provides an opportunity to test interventions targeted for prevention of Alzheimer’s
disease neuropathology and dementia in Down syndrome.
Discussion: In considering clinical trial designs, however, there are several challenges that we believe will be critical
to examine further. These include: accuracy in dementia, mild cognitive impairment and preclinical Alzheimer’s
disease diagnoses in Down syndrome; clinical trial outcome measures appropriate for individuals with Down
syndrome; in vivo imaging outcome measures (and practical considerations); and contributions of medical
co-morbidities to disease progression. Also, when studies are designed, the molecular target may appear to be
obvious (for example, targeting beta-amyloid pathology), but chromosome 21 has over 200 additional genes that
could influence both positive and negative clinical trial outcomes.
Summary: Observational longitudinal studies of aging in Down syndrome will be critically important as there is a
need to establish sensitive clinical outcome measures and understand the consequences of gene overexpression in
relation to specific interventions.
Introduction
Aging people with Down syndrome (DS) are at increased
risk for cognitive decline, dementia, and Alzheimer’s
disease (AD). In DS adults ranging from 40 to 49 years of
age, up to 55% may be demented, and between 50 and
59 years, prevalence ranges from 4% to 55% [1,2]. By the
age of 40 years, virtually all DS adults have sufficient senile
plaques - containing the beta-amyloid (Aβ) peptide - and
neurofibrillary tangles for a neuropathological diagnosis of
AD [3]. Aβ pathology, specifically, can be observed in dif-
fuse plaques in patients as young as 30 years of age. The
early age of onset of Aβ and the development of AD in DS
is thought to reflect increased expression of the amyloid
precursor protein (APP) on chromosome 21. Interestingly,
there is dissociation between the age of onset of AD
neuropathology (approximately 40 years) and age of onset
of dementia (approximately 50 years). Although not all
adults with DS become demented (despite the presence of
AD neuropathology [2,4]), the age dependency of the de-
velopment of AD neuropathology in DS provides a unique
opportunity to develop preventative interventions that can
be beneficial in delaying or preventing dementia.
Discussion
Diagnosing dementia in down syndrome and clinical trial
outcome measures
Systematic diagnostic criteria for mild cognitive impairment
or dementia in DS have not been clearly established [5-7].
Similarly, in DS, it is not entirely clear what clinical out-
come measures might be most sensitive to prevention or
treatment approaches as multiple studies nationally and
internationally have used different clinical outcomes to de-
tect developmental changes in DS along with treatment
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benefits. It is critical to identify outcome measures that can
be used across clinical trials (along with a broad age range),
and they will be substantially different from those used in
sporadic AD clinical trials. Indeed, concerns have been
raised in regard to the selection of the neuropsychological
measures for sporadic AD clinical trials that may be not as
sensitive to treatment outcomes as was initially thought [8].
Clinical trials in sporadic AD are relying more upon im-
aging and cerebrospinal fluid (CSF) approaches to both
identify appropriate persons for inclusion in studies and
to potentially monitor both treatment benefits and adverse
effects [8]. There are several structural imaging studies in
DS with age in the literature (reviewed in [9]) but fewer
studies using amyloid positron emission tomography
(PET) imaging ligands [10]. Given that the age of onset of
clinical dementia in DS is over 50 years of age and can be
variable (including some individuals who do not appar-
ently develop dementia), further longitudinal PET studies
would be critical to establish its use as a clinical outcome
measure independent of cognitive measures.
Practical considerations in clinical trials for down syndrome
The practical considerations of initiating a clinical trial
for people with DS should be discussed. Identifying and
recruiting DS adults can be a slow process, although the
new DS-Connect registry [11] will significantly enhance
this effort. Retention may also be challenging as various
co-morbidities that develop with age in DS will need to be
managed. An excellent example comes from a 2-year anti-
oxidant trial in demented adults with DS in which clinical
decline was influenced by the presence of seizures [12]. Al-
though obtaining blood samples from persons with DS is
not without challenges, this can often be readily accom-
plished. However, given the impact of DS physiology, intel-
lectual disability, and associated anxiety over more invasive
procedures, CSF samples are likely to be more difficult to
acquire. Further, more invasive techniques are likely to pro-
duce added concerns for participants, family, and caregivers
that would likely also lead to increased institutional review
board concerns over consent (family and/or caregiver) ver-
sus assent by the participant. Similarly, our own experience
suggests that imaging studies in DS are associated with
additional challenges, including motion artifact, unwilling-
ness to enter the scanner, and an inability to tolerate the
prone position for great lengths of time [13].
Selection of the intervention approach
Which intervention is appropriate? One of the most con-
sistent features of aging in DS is the progressive accumu-
lation of Aβ in patients over the age of 30 years. Targeting
the elimination or reduction of Aβ is a very reasonable
goal for adults with DS as a prevention approach. Will
preventing or slowing Aβ deposition in adults with DS
prevent cognitive decline and dementia as they age? For
this discussion, we will focus on Aβ-targeted therapies
(many different prevention approaches that are vaccine-
based or pharmacological could be considered) and
challenges for clinical trials for adults with DS that
are, we suggest, unique to this vulnerable cohort.
It is important to remember that chromosome 21 con-
tains over 200 genes, affecting multiple protein pathways
and domains that have not been fully explored in relation
to aging and that could significantly, and possibly ad-
versely, affect clinical trial outcomes. For example, neuro-
inflammation is a feature of the DS aging brain, but
studies are still limited (reviewed in [14]). Interestingly,
approximately a dozen genes on chromosome 21 are dir-
ectly related to inflammation. This suggests a disruption in
the inflammatory milieu in DS that could directly modulate
responses to interventions that include immunotherapy or
anti-inflammatories. Targeting APP overexpression by beta-
secretase (beta-amyloid cleaving enzyme, or BACE) inhibi-
tors, which are still considered a possible therapy and are
currently in clinical trials in AD [15], is also promising.
However, BACE1 has multiple neuronal substrates that can
include several genes overexpressed in DS (for example, the
neuroinflammatory gene IFNAR2), not to mention that
BACE2 (a homologous protein) is on chromosome 21,
which may complicate the interpretation of the outcomes.
Summary
Careful studies establishing longitudinal aging outcomes
in non-treated individuals with DS will greatly inform pre-
vention studies similar to the planned Down Syndrome
Biomarker Initiative study [16]. Overall, establishing
appropriate clinical outcome measures and considering
possible complications related to the fact that multiple
genes are overexpressed in DS that can affect inflammation,
oxidative stress, mitochondrial dysfunction, and other
mechanisms are important to consider in terms of both
efficacy and adverse events.
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